Metastatic Colorectal Cancer (CRC) (DBCOND0134580)

Identifiers

Synonyms
Metastatic Colo-rectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancers / Colorectal Cancer, Metastatic / Metastatic Cancer Colorectal / MCRC / Metastatic malignant neoplasm to colon and/or rectum (disorder) / Large intestine metastases / Metastatic malignant neoplasm to large intestine (disorder) / Metastases to large intestine

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Aflibercept
A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer
Bevacizumab
A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Cetuximab
An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Encorafenib
A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations.
Fruquintinib
A VEGF receptor inhibitor used to treat metastatic colorectal cancer.
Irinotecan
A topoisomerase inhibitor used to treat metastatic carcinoma of the colon or rectum and pancreatic adenocarcinoma.
Levoleucovorin
A folate analog used after high dose methotrexate for osteosarcoma, to reduce the toxic effects of folate analogs, and with 5-fluorouracil in palliative treatment of advanced metastatic colorectal cancer.
Nivolumab
A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
Panitumumab
A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Ramucirumab
An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
Regorafenib
A kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma.
Tipiracil
A thymidine phosphorylase inhibitor used as an adjunct treatment of adult patients with certain types of gastric or colorectal malignancies.
Trifluridine
A nucleoside metabolic inhibitor used to treat keratoconjunctivitis and epithelial keratitis caused by simplex virus, and as a part of chemotherapy for certain types of metastatic gastrointestinal cancers.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT01867918
LOTCOL Study: Local Treatment of Colo-rectal Liver MetNo drug interventionstreatmentNot Availableterminated
NCT01358812
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancertreatment2completed
NCT06621173
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC PatientsNo drug interventionstreatment0not_yet_recruiting
NCT05286814
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinomatreatment2recruiting
NCT05839951
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World ConditionsNot AvailableNot Availableactive_not_recruiting
NCT02649790
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indicationstreatment1 / 2active_not_recruiting
NCT05970302
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCtreatment2recruiting
NCT04856787
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCtreatment2 / 3recruiting
NCT03511963
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRCtreatment3unknown_status
NCT02069704
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patientstreatment1completed
NCT01705002
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.treatment1completed
NCT00594984
Phase I/II Combination With Irinotecan- Erbituxtreatment1 / 2completed
NCT05420909
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)No drug interventionsNot AvailableNot Availablecompleted
NCT06089330
A Study of JMT101 in Patients With Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT03829462
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patientstreatment3recruiting
NCT03164655
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Networktreatment2completed
NCT05674526
A Phase 1b Study of WU-NK-101 in Combination With Cetuximabtreatment1recruiting
NCT06625515
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients with Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersNo drug interventionstreatment1not_yet_recruiting
NCT04564898
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.treatment1 / 2active_not_recruiting
NCT05480306
Phase 2 Study of DKN-01 in Colorectal Cancertreatment2active_not_recruiting
NCT05759728
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal CancerNo drug interventionstreatment1 / 2recruiting
NCT06589830
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT06555003
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastasestreatment3not_yet_recruiting
NCT06283303
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancertreatment1not_yet_recruiting
NCT01315990
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthematreatment4unknown_status
NCT05995990
Raman Spectroscopy for Liver Tumours Following Liver SurgeryNo drug interventionsbasic_scienceNot Availablecompleted
NCT05808790
Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative RadiotherapyNo drug interventionstreatmentNot Availablenot_yet_recruiting
NCT01670721
Colorectal Cancer Metastatictreatment3completed
NCT03364621
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer TherapyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT03982121
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapytreatment1withdrawn
NCT06440902
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNAdiagnostic2recruiting
NCT03800602
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancertreatment2completed
NCT05129787
Ablation vs Resection of Colorectal Cancer Liver MetastasesNo drug interventionstreatmentNot Availablerecruiting
NCT01721954
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal CancerNo drug interventionstreatment3completed
NCT06353854
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)No drug interventionsNot AvailableNot Availablerecruiting
NCT02959151
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver MalignancyNo drug interventionstreatment1 / 2unknown_status
NCT02390947
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)treatment3completed
NCT04169347
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancertreatment2active_not_recruiting
NCT02085005
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancertreatment2withdrawn
NCT05589597
EO4010 in Previously Treated Metastatic Colorectal Carcinomatreatment1 / 2recruiting
NCT01959061
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastasestreatment4unknown_status
NCT04874207
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenibtreatment4active_not_recruiting
NCT04525807
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella TheoryNo drug interventionsNot AvailableNot Availableunknown_status
NCT02139215
Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT00442637
Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinomatreatment3unknown_status
NCT05584137
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRCtreatment2suspended
NCT03531632
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancertreatment1 / 2completed
NCT05625932
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancerprevention3recruiting
NCT01508000
Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastasestreatment2terminated
NCT01298570
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancertreatment2completed
NCT01661270
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapytreatment3completed
NCT05200442
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancertreatment1 / 2recruiting
NCT06379399
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRCtreatment1 / 2recruiting
NCT04888806
A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasistreatment2not_yet_recruiting
NCT03923036
Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT03803436
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver TransplantationNo drug interventionstreatment2recruiting
NCT01053013
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal CancerNo drug interventionstreatment2completed
NCT04543019
Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT06008119
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancertreatment3not_yet_recruiting
NCT05475041
Perioperative Outcomes of Simultaneous Colorectal and Liver ResectionsNo drug interventionsNot AvailableNot Availablecompleted
NCT03657641
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancertreatment1 / 2active_not_recruiting
NCT01163396
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancertreatment2completed
NCT02316496
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Studytreatment2terminated
NCT06300463
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastasestreatment2recruiting
NCT05665322
Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver MetastasesNo drug interventionstreatmentNot Availablerecruiting
NCT04157322
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal MetastasisNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT04867525
Registry Platform Colorectal CancerNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT04790448
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancertreatment1 / 2completed
NCT03563157
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccinetreatment1 / 2active_not_recruiting
NCT02135757
Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT05678257
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancertreatment2terminated
NCT06540326
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximabtreatment2not_yet_recruiting
NCT04595266
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Diseasetreatment2recruiting
NCT05913674
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)No drug interventionsother2recruiting
NCT05062720
Local Consolidative Therapy in Colorectal CancerNo drug interventionstreatment2withdrawn
NCT05160727
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancertreatment2recruiting
NCT06447727
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLMNot AvailableNot Availablerecruiting
NCT03751176
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectaltreatment2unknown_status
NCT03439462
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancertreatment1 / 2completed
NCT03941080
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT01955629
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patienttreatment1 / 2terminated
NCT01540344
Combined Anticancer Treatment of Advanced Colon CancerNo drug interventionstreatment2terminated
NCT01640444
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)treatment2completed
NCT04730544
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.treatment2recruiting
NCT03144804
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancertreatment2completed
NCT03038568
Assessing How Normal Variations in CT Scanning Affects Its InterpretationNo drug interventionsNot AvailableNot Availablerecruiting
NCT03792269
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRCtreatment2unknown_status
NCT04940546
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patientstreatment1 / 2active_not_recruiting
NCT03251612
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal CancerNo drug interventionstreatment2completed
NCT01522612
Colorectal Cancer (CRC) Cetuximab Elderly Frailtreatment2terminated
NCT01910610
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancertreatment3active_not_recruiting
NCT03193710
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism InvolvedNot AvailableNot Availableunknown_status
NCT04108481
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancertreatment1 / 2suspended
NCT03597581
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancertreatment1recruiting
NCT04751955
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)treatment1 / 2withdrawn
NCT03549338
Sym004 Versus Futuximab or Modotuximab in Patients With mCRCtreatment2terminated
NCT02380443
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal CancerNo drug interventionstreatment2completed
NCT06547203
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Studytreatment2recruiting
NCT03388190
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatintreatment2active_not_recruiting
NCT03898102
Zinc Supplement in Regorafenib Treated mCRC Patienttreatment2completed
NCT02149784
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer PatientsNo drug interventionstreatment3unknown_status
NCT01571284
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimentreatment3completed
NCT03733184
Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT03149679
The p53 Colorectal Cancer Trialtreatment2terminated
NCT06332079
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patientstreatment2recruiting
NCT04262687
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltratetreatment2recruiting
NCT01317433
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal CancertreatmentNot Availableterminated
NCT01646554
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastasestreatment2 / 3withdrawn
NCT03983954
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumorstreatment1active_not_recruiting
NCT03488953
Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver MetastasesNo drug interventionstreatmentNot Availablerecruiting
NCT01471353
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancertreatment2completed
NCT05501353
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics MethodsNo drug interventionsNot AvailableNot Availablerecruiting
NCT02751177
Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal CancerNo drug interventionsdiagnosticNot Availablecompleted
NCT06282445
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancertreatment2recruiting
NCT04550897
A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer PatientsNo drug interventionsother1 / 2recruiting
NCT05513183
Severe Neutropenia After HIPEC Using Mitomycin-CNo drug interventionsNot AvailableNot Availablecompleted
NCT01762293
A Study of Famitinib in Patients With Advanced Colorectal Cancertreatment2completed
NCT03503071
Quality of Life After Cytoreductive Surgery and Intraperitoneal ChemotherapyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04148378
A Pilot Study to Explore the Role of Gut Flora in Colorectal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT03007407
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapytreatment2completed
NCT01382407
Does Acne Rash During Adolescence Predict Skin Reaction to CetuximabNot AvailableNot Availablecompleted
NCT04368507
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patientstreatment1 / 2completed
NCT03556956
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancertreatment2 / 3completed
NCT05700656
Galunisertib Combined With Capecitabine in Advanced CRC With PMtreatment1 / 2recruiting
NCT02948985
Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRCNo drug interventionsNot AvailableNot Availableunknown_status
NCT06456515
Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRCtreatmentNot Availablenot_yet_recruiting
NCT05057052
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasistreatment2recruiting
NCT02350400
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).No drug interventionstreatment1completed
NCT03750175
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -No drug interventionsNot AvailableNot Availablecompleted
NCT06027775
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT02179970
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancerstreatment1completed
NCT03705442
Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancersupportive_care2unknown_status
NCT04898842
Feasibility Study of a 4 Stage Bowel Obstruction Cancer DietNo drug interventionstreatmentNot Availablecompleted
NCT04999306
Feasibility of 2 Interventions to Reduce Fatigue in Patients With Chemotherapy for Metastatic Colorectal CancerNo drug interventionssupportive_careNot Availablerecruiting
NCT04854213
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)No drug interventionsotherNot Availablerecruiting
NCT05261113
CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT06522919
Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT06283134
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancertreatment1not_yet_recruiting
NCT05611034
In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lungtreatment1recruiting
NCT03142516
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Statustreatment2completed
NCT05513716
Molecular Characterisation of Colorectal Cancer Peritoneal MetastasesNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT03202758
Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCtreatment1 / 2completed
NCT05727163
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patientstreatment2recruiting
NCT02171286
The Oncopanel Pilot (TOP) StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01943786
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-CetuximabNot AvailableNot Availableunknown_status
NCT03647839
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancertreatment2completed
NCT01909830
Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patientstreatment2completed
NCT04245865
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancertreatment2recruiting
NCT05353582
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal MetastasesNo drug interventionstreatment2not_yet_recruiting
NCT04799431
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancertreatment1withdrawn
NCT05736731
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionNo drug interventionstreatment1 / 2recruiting
NCT05068531
Early Detection of Treatment Failure in Metastatic Colorectal Cancer PatientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT03133273
Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)No drug interventionsotherNot Availablecompleted
NCT01483027
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal CancerNo drug interventionstreatmentNot Availablecompleted
NCT01892527
Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjectstreatment2completed
NCT01982227
Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.Not AvailableNot Availablecompleted
NCT05289076
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo ModelNo drug interventionstreatment1 / 2recruiting
NCT04030260
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancertreatment2recruiting
NCT05243862
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.treatment2active_not_recruiting
NCT05092880
Radioembolization in Elderly/ Fragile Patients With mCRCNo drug interventionstreatment2recruiting
NCT01668680
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinomatreatment2terminated
NCT01932489
The Jules Bordet Institute Molecular Profiling Program Feasibility TrialNo drug interventionsotherNot Availablecompleted
NCT06449989
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT05273489
Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.No drug interventionsNot AvailableNot Availablecompleted
NCT02286492
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal CancerNot AvailableNot Availableapproved_for_marketing
NCT03697044
Irinotecan Drug-eluting Bead Liver Embolisation RegistryNo drug interventionsNot AvailableNot Availableunknown_status
NCT04721301
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trialtreatment1completed
NCT03173001
Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer PathogenesisNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT06414304
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor TherapyNo drug interventionsNot AvailableNot Availablerecruiting
NCT04031872
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)treatment1 / 2unknown_status
NCT01882868
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japantreatment2completed
NCT04081168
COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave AblationNo drug interventionstreatmentNot Availablerecruiting
NCT03167268
Panitumumab Skin Toxicity Prevention Trialsupportive_care2unknown_status
NCT04607668
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):treatment3terminated
NCT00741481
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.No drug interventionsNot AvailableNot Availablecompleted
NCT05248581
Living Donor Liver Transplant for Unresectable Colorectal Liver MetastasesNo drug interventionsNot AvailableNot Availablerecruiting
NCT04684095
The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal CancerNo drug interventionsotherNot Availableunknown_status
NCT03213314
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver MalignanciesNo drug interventionsdiagnosticNot Availablecompleted
NCT06018714
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Studytreatment2recruiting
NCT03470350
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancertreatment1 / 2withdrawn
NCT03775850
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumorstreatment1completed
NCT04482608
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and SurvivalNo drug interventionsNot AvailableNot Availablecompleted
NCT03717038
Sym004 Versus TAS-102 in Patients With mCRCtreatment3withdrawn
NCT01249638
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRCtreatment3unknown_status
NCT04517643
TheraSphere® For Treatment of Metastases in LiverNo drug interventionsotherNot Availablecompleted
NCT06603818
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)treatment2not_yet_recruiting
NCT01174121
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancertreatment2recruiting
NCT02980510
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patientstreatment2active_not_recruiting
NCT06106308
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutationtreatment2recruiting
NCT06149481
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)treatment1 / 2recruiting
NCT06625775
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)treatment1not_yet_recruiting
NCT04660812
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.treatment1 / 2active_not_recruiting
NCT04929223
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)treatment1recruiting
NCT04952753
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRCtreatment2active_not_recruiting
NCT05639413
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal CancerNo drug interventionspreventionNot Availablerecruiting
NCT05985954
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapytreatment1recruiting
NCT06137170
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of TreatmentNot AvailableNot Availableactive_not_recruiting
NCT06228326
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNo drug interventionstreatment1recruiting
NCT06245356
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancertreatment2not_yet_recruiting
NCT06403709
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patientstreatment2active_not_recruiting
NCT06412198
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutationstreatment1 / 2recruiting
NCT06493760
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patientstreatment2recruiting
NCT06557278
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT06614192
A Study to Assess Adverse Events and How Intravenously (IV) Infused ABBV-400 Moves Through the Body as a Monotherapy Compared to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancertreatment3not_yet_recruiting
NCT05310643
Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapytreatment2recruiting
NCT03307603
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancertreatment1 / 2withdrawn
NCT05229003
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCtreatment2recruiting
NCT02296203
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).treatment2unknown_status
NCT04826003
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatmenttreatment1 / 2active_not_recruiting
NCT01862003
Phase I/II Trial of Antagonism of HER in GI Cancertreatment2completed
NCT04866290
HepaSphere™ Microspheres Prospective RegistryNo drug interventionsNot AvailableNot Availablecompleted
NCT05659290
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancertreatment2recruiting
NCT00717990
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatmenttreatment2terminated
NCT03210064
Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patientstreatment2unknown_status
NCT02453464
A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancertreatment1unknown_status
NCT02271464
Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancertreatment2completed
NCT03832621
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancertreatment2completed
NCT05130021
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancertreatment2unknown_status
NCT01591421
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.treatment1 / 2completed
NCT02743221
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapytreatment2completed
NCT01531621
A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in FinlandNo drug interventionsNot AvailableNot Availablerecruiting
NCT05962502
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapytreatment2recruiting
NCT03220984
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal CancerNo drug interventionstreatment2unknown_status
NCT01399684
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancertreatment2completed
NCT00827684
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutationstreatment2completed
NCT00191984
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancertreatment2completed
NCT03295084
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumorsother1completed
NCT02216487
Trial of FOLF(HA)Iri With Cetuximab in mCRCtreatment2unknown_status
NCT05443087
TARGETed Therapy Drug MONITOring in DIGestive OncologyNo drug interventionstreatmentNot Availablerecruiting
NCT00396487
Tailored Treatment in Metastatic Colorectal Cancertreatment3terminated
NCT02278133
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutationstreatment1 / 2completed
NCT00844233
Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal CancerNo drug interventionstreatment1 / 2completed
NCT00969033
CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatintreatment2terminated
NCT04466254
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancertreatment2unknown_status
NCT00819754
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancertreatment1 / 2terminated
NCT04513951
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patientstreatment2active_not_recruiting
NCT03206151
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancertreatment3active_not_recruiting
NCT00625651
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancertreatment1 / 2completed
NCT00558051
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal CancerNo drug interventionsbasic_science1completed
NCT06415851
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumabtreatment2not_yet_recruiting
NCT03721653
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patientstreatment2completed
NCT02083653
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancertreatment2completed
NCT01067053
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.treatment2unknown_status
NCT02612077
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)Not AvailableNot Availablecompleted
NCT02310477
Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life SettingNot AvailableNot Availablecompleted
NCT03880877
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancertreatment2unknown_status
NCT06118047
Crisaborole Ointment for Skin Toxicity Induced by Cetuximabtreatment2recruiting
NCT01243047
Intermittent Versus Continuous Tarceva StudyNo drug interventionstreatment2completed
NCT04689347
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.treatment1unknown_status
NCT01460745
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical PracticeNo drug interventionsNot AvailableNot Availablecompleted
NCT00316745
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancertreatment3suspended
NCT05531045
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic AdenocarcinomaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT02476045
Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)treatment2unknown_status
NCT04188145
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancertreatment3recruiting
NCT02205398
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapytreatment1terminated
NCT03791398
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRCtreatment1 / 2terminated
NCT01640405
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cellstreatment3completed
NCT00813605
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinomatreatment2completed
NCT05787197
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver MetastasesNo drug interventionsNot AvailableNot Availablerecruiting
NCT00489697
Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver MetastasesNo drug interventionsdiagnosticNot Availablecompleted
NCT01290783
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRCtreatment3unknown_status
NCT06202183
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE TrialNo drug interventionssupportive_careNot Availablerecruiting
NCT00514761
Phase II Efficacy Study of AZD6244 in Colorectal Cancertreatment2completed
NCT00986661
A Study to Assess PV-10 Chemoablation of Cancer of the Livertreatment1active_not_recruiting
NCT01733628
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT01117428
Sym004 in Patients With Advanced Solid Tumorstreatment1 / 2completed
NCT04008511
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancertreatment1 / 2unknown_status
NCT03532711
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal CancerNot AvailableNot Availablecompleted
NCT03584711
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutationtreatment2active_not_recruiting
NCT00475293
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCtreatment2completed
NCT00614393
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)treatment2completed
NCT03426371
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody TrialNo drug interventionstreatment3unknown_status
NCT02437071
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patientstreatment2active_not_recruiting
NCT02575378
Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal CancerNo drug interventionstreatment4unknown_status
NCT02817178
Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal CancerNo drug interventionsotherNot Availablecompleted
NCT02723578
Pemetrexed and Erlotinib for Metastatic Colorectal Cancertreatment2completed
NCT03908788
Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) TherapyNo drug interventionsdiagnosticNot Availableactive_not_recruiting
NCT02535988
Abscopal Effect for Metastatic Colorectal Cancertreatment2withdrawn
NCT02994888
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal CancerNot AvailableNot Availablecompleted
NCT05093907
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancertreatment1 / 2unknown_status
NCT03435107
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancertreatment2active_not_recruiting
NCT06551207
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCtreatmentNot Availablerecruiting
NCT03259009
RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)No drug interventionsNot AvailableNot Availableunknown_status
NCT01791309
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancertreatment1completed
NCT06341309
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancertreatment1 / 2not_yet_recruiting
NCT02414009
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patientstreatment2completed
NCT03122509
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancertreatment2completed
NCT05291156
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategytreatment2recruiting
NCT06296056
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of CareNo drug interventionstreatment1not_yet_recruiting
NCT03602885
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment OptionsNo drug interventionshealth_services_researchNot Availablecompleted
NCT02423785
Ocular Blood Flow in Colorectal Cancer PatientsNo drug interventionsNot AvailableNot Availableterminated
NCT00835185
Study of IMC-11F8 in Participants With Colorectal Cancertreatment2completed
NCT04073615
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)treatment1terminated
NCT05447715
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT04224415
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRCtreatment2completed
NCT06363552
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT03829852
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) PatientsNot AvailableNot Availablecompleted
NCT05201352
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidinetreatment1 / 2recruiting
NCT04735900
lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer PatientsNo drug interventionsdiagnosticNot Availableunknown_status
NCT05775900
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancertreatment1 / 2recruiting
NCT01040000
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancertreatment1 / 2completed
NCT05725200
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancertreatment2recruiting
NCT02256800
Escalated Dose of Irinotecan in mCRCtreatmentNot Availablecompleted
NCT05127759
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationNo drug interventionstreatment2active_not_recruiting
NCT00294359
The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancertreatment2 / 3completed
NCT04034459
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCtreatment2active_not_recruiting
NCT04475159
Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II TrialNo drug interventionstreatment2unknown_status
NCT04194359
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancertreatment2active_not_recruiting
NCT05793775
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT02597075
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line ChemotherapyNo drug interventionstreatmentNot Availableterminated
NCT00752570
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinomatreatment2completed
NCT04965870
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in GreeceNot AvailableNot Availablecompleted
NCT01472770
A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancertreatment2completed
NCT06195670
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRCtreatment1 / 2not_yet_recruiting
NCT00911170
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Studysupportive_care3completed
NCT05513742
A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNo drug interventionstreatment2active_not_recruiting
NCT02028442
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patientstreatment1 / 2completed
NCT01386242
Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancertreatment2completed
NCT04835142
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRCNo drug interventionstreatment3completed
NCT00862342
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)treatment2completed
NCT03542799
EGFR-IL12-CART Cells for Patients With Metastatic Colorectal CancerNo drug interventionstreatment1unknown_status
NCT02332499
Study of Anlotinib in Patients With Metastatic Colorectal Cancer(mCRC)(ALTER0703)treatment2 / 3completed
NCT04456699
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)treatment3completed
NCT03828799
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerNo drug interventionsother1 / 2active_not_recruiting
NCT03867799
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancertreatment2active_not_recruiting
NCT03008499
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal CancerNo drug interventionstreatment1 / 2completed
NCT03547999
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCtreatment2active_not_recruiting
NCT03665506
Trifluridin/tipirACil in meTastatIc Colorectal CancerNot AvailableNot Availablecompleted
NCT01039506
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)Not AvailableNot Availablecompleted
NCT05412706
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapytreatment2withdrawn
NCT06252649
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutationtreatment3recruiting
NCT05462236
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancertreatment2recruiting
NCT00851136
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)treatment1completed
NCT04450836
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancertreatment2active_not_recruiting
NCT02542436
Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK PopulationNo drug interventionsNot AvailableNot Availablewithdrawn
NCT04479436
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal CancerNo drug interventionstreatment2terminated
NCT04561336
Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancertreatment2completed
NCT05743036
ZN-c3 in Adult Participants With Metastatic Colorectal Cancertreatment1 / 2recruiting
NCT00364013
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacytreatment3completed
NCT06485713
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRCtreatment2recruiting
NCT01651013
Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-RasNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05110118
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjectstreatment1completed
NCT04230018
The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT01605318
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancertreatment1 / 2terminated
NCT05316818
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal CarcinomaNo drug interventionstreatment2completed
NCT05631041
Effect of Silymarin in Metastatic Colorectal Cancer Patientstreatment3recruiting
NCT01022541
Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancertreatment2completed
NCT01228734
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patientstreatment3completed
NCT04948034
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)treatment2unknown_status
NCT03391934
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancertreatment3recruiting
NCT01571024
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancertreatment1completed
NCT02835924
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRCtreatment2completed
NCT00689624
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancertreatment2completed
NCT02489916
Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancertreatment1 / 2completed
NCT01516216
Study of Vitamin D in Untreated Metastatic Colorectal Cancertreatment2completed
NCT02339116
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRCtreatment3unknown_status
NCT04393116
Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT00563316
Effect of Panitumumab on the Pharmacokinetics of Irinotecantreatment1completed
NCT01161316
Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumourstreatment2completed
NCT03340558
Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancerbasic_science2withdrawn
NCT04793958
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)treatment3active_not_recruiting
NCT05690035
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancertreatment2withdrawn
NCT01154335
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancertreatment1completed
NCT00806663
FOLFIRI and Sunitinib in Metastatic Colorectal Cancertreatment2completed
NCT01220063
RSHF in Colorectal Cancertreatment2completed
NCT03935763
Management of Metastatic Colorectal Cancer: A Clinical and Patient PerspectiveNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT00958386
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)treatment2completed
NCT00630786
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Studytreatment1 / 2completed
NCT06563986
FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancertreatment2recruiting
NCT04322539
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancertreatment3active_not_recruiting
NCT05551039
An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in EuropeNo drug interventionsNot AvailableNot Availablecompleted
NCT03168139
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancertreatment1 / 2completed
NCT01878422
Sequential Treatment Strategy for Metastatic Colorectal Cancertreatment3completed
NCT03231722
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTStreatment3completed
NCT04920422
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.No drug interventionsNot AvailableNot Availablecompleted
NCT00205322
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancertreatment2completed
NCT06225622
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancertreatment1recruiting
NCT02282722
Improving Informed Consent for Palliative ChemotherapyNo drug interventionsotherNot Availablecompleted
NCT03132025
Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancertreatment2unknown_status
NCT02045030
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancertreatment2terminated
NCT01124630
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatmentstreatment1completed
NCT03688230
Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.treatment2withdrawn
NCT00891930
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumabtreatment2completed
NCT05635630
Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic InterventionNo drug interventionsdiagnosticNot Availablerecruiting
NCT01693848
"Cancersensor" Metastasis ResectionNo drug interventionsNot AvailableNot Availablecompleted
NCT05487248
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer PatientsNo drug interventionsdiagnosticNot Availablerecruiting
NCT01832948
Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancertreatment2unknown_status
NCT03912857
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancertreatment2unknown_status
NCT01767857
A Phase III Study of Xilonix in Patients With Advanced Colorectal CancerNo drug interventionstreatment3terminated
NCT04513457
Chemotherapy for Resectable Colorectal Liver MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT02129257
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancertreatment2completed
NCT02624726
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatmenttreatment2unknown_status
NCT01639326
Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1treatment2unknown_status
NCT03604926
Immunophenotyping of Metastases From Colorectal CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT01651026
Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCtreatment1 / 2recruiting
NCT03186326
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancertreatment2unknown_status
NCT00378066
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancertreatment2completed
NCT02117466
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancertreatment1 / 2terminated
NCT01576666
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumorsother1completed
NCT02827565
Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal CancerNo drug interventionsotherNot Availablecompleted
NCT02615574
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancertreatment2withdrawn
NCT05103020
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastasestreatment2recruiting
NCT02079220
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancertreatment2withdrawn
NCT01669720
Adjuvant Aflibercept for Metastatic Colorectal Cancertreatment2terminated
NCT05266820
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancertreatment2unknown_status
NCT04659382
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancertreatment2recruiting
NCT04656782
EORTC-endorsed, Prospective European Multicenter Imaging Survey and ProtocolNo drug interventionsNot AvailableNot Availableunknown_status
NCT02870582
Donafenib for Previously Treated Metastatic Colorectal Cancertreatment3completed
NCT00660582
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumortreatment2completed
NCT05004831
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCtreatment2unknown_status
NCT00422773
Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancertreatment1 / 2completed
NCT05223673
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancertreatment3terminated
NCT01991873
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancertreatment2completed
NCT00959127
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancertreatment1completed
NCT02331927
PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancertreatment2unknown_status
NCT03645876
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancertreatment2terminated
NCT04926376
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRCNo drug interventionstreatmentNot Availablecompleted
NCT02055560
Retrospective Evaluation of 5-FU Exposure Optimization in CRC PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01410760
PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver MetastasesNo drug interventionsdiagnostic0unknown_status
NCT03182894
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancertreatment1 / 2withdrawn
NCT03401294
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.treatment2not_yet_recruiting
NCT03081494
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancertreatment1completed
NCT01949194
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkerstreatment2unknown_status
NCT03031691
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancertreatment1completed
NCT03295591
Circulating Tumor Cells in mCRC for Liver ResectionNo drug interventionsNot AvailableNot Availableunknown_status
NCT01889680
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancertreatment2withdrawn
NCT01387880
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancertreatment2completed
NCT02063529
FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancertreatment2completed
NCT00255229
Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrheatreatment2completed
NCT00337389
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.treatment3unknown_status
NCT06501989
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT03222089
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRCtreatment2withdrawn
NCT03869892
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.treatment3active_not_recruiting
NCT05608044
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancertreatment2active_not_recruiting
NCT05940844
Study of OB-002 in Patients With Refractory Metastatic CancerNo drug interventionstreatment1not_yet_recruiting
NCT03256344
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastasesother1completed
NCT01134640
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing TreatmentNo drug interventionsNot AvailableNot Availablecompleted
NCT06242067
Second-line Treatment of Metastatic Colorectal Cancertreatment2recruiting
NCT01832467
Cetuximab Rechallenge Studytreatment2completed
NCT00784667
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinibtreatment2unknown_status
NCT01051167
Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancertreatment2completed
NCT05555901
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancertreatment2recruiting
NCT06202001
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patientstreatment1 / 2recruiting
NCT04166604
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacytreatment2active_not_recruiting
NCT03274804
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCtreatment1completed
NCT02851004
Special Combination of BBI608 and Pembrolizumabtreatment1 / 2terminated
NCT06060704
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.treatment2recruiting
NCT01024504
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancertreatment2completed
NCT01053104
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity MonitoringNo drug interventionsNot AvailableNot Availablecompleted
NCT03405272
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRCNo drug interventionstreatment2unknown_status
NCT01661972
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancertreatment1 / 2completed
NCT02973672
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or PancreasNo drug interventionsdiagnostic1 / 2completed
NCT05755672
On-treatment Biomarkers in Metastatic Colorectal Cancer for LifeNo drug interventionsNot AvailableNot Availablerecruiting
NCT05721872
Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancertreatment1 / 2recruiting
NCT06313268
Safety of Effivia®, a Bevacizumab BiosimilarNot AvailableNot Availablerecruiting
NCT00920868
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinibtreatment1completed
NCT01996969
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal CancerscreeningNot Availablecompleted
NCT02060669
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancertreatment3terminated
NCT02345746
Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasistreatment2withdrawn
NCT02568046
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patientstreatment1 / 2terminated
NCT05201612
Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).treatment2recruiting
NCT03350412
Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical TrialsNo drug interventionsNot AvailableNot Availableunknown_status
NCT02673710
A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With BevacizumabNo drug interventionsNot AvailableNot Availablecompleted
NCT03785210
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancerstreatment2completed
NCT01212510
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal CancerNo drug interventionsdiagnosticNot Availablecompleted
NCT03829410
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutationtreatment1 / 2completed
NCT04889495
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNot AvailableNot Availablenot_yet_recruiting
NCT01531595
Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancertreatment2recruiting
NCT04126655
Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and CalciumfolinateNo drug interventionstreatment1 / 2unknown_status
NCT00207155
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancertreatment1completed
NCT05004350
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.treatment2active_not_recruiting
NCT01311050
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT00233623
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancertreatment2withdrawn
NCT01811108
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT05438108
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRCtreatment2unknown_status
NCT01718808
Cetuximab for Elderly Patients With mCRCtreatment2terminated
NCT03564938
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).treatment4completed
NCT00418938
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trialtreatment2completed
NCT03286738
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT03146338
Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)No drug interventionspreventionNot Availableunknown_status
NCT01741038
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal CancerNo drug interventionstreatment2 / 3withdrawn
NCT06225843
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasistreatment2recruiting
NCT01280643
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal CancertreatmentNot Availableterminated
NCT01912443
Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT04753203
Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patientstreatment1 / 2active_not_recruiting
NCT01596790
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal CancerNo drug interventionsotherNot Availablecompleted
NCT01703390
Biomarker Directed Treatment in Metastatic Colorectal Cancertreatment2completed
NCT02173990
Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).treatment2terminated
NCT03977090
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancertreatment1unknown_status
NCT05634590
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT03176264
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancertreatment1terminated
NCT00252564
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancertreatment3completed
NCT02210364
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).treatment1completed
NCT02310464
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjectstreatment1completed
NCT02043821
Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological MarkertreatmentNot Availableunknown_status
NCT01249521
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancertreatment2unknown_status
NCT05158621
A Screening Study Targeting Tumor-specific AntigensNo drug interventionsNot AvailableNot Availablecompleted
NCT06513221
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimabtreatment2not_yet_recruiting
NCT02623621
Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal CancerNot AvailableNot Availablecompleted
NCT04495621
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)treatment1 / 2completed
NCT00494221
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXtreatment1 / 2completed
NCT06039202
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancertreatment2not_yet_recruiting
NCT01273402
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancertreatment1withdrawn
NCT04247984
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancertreatment2completed
NCT01919879
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancertreatment2completed
NCT03291379
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignanciestreatment0completed
NCT02872779
Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal CancerNo drug interventionsdiagnosticNot Availableunknown_status
NCT03288987
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancertreatment3completed
NCT06425133
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancerstreatment2not_yet_recruiting
NCT01652833
European Physician Survey of EGFR Inhibitor Prescribing PatternsNo drug interventionsNot AvailableNot Availablecompleted
NCT03374254
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)treatment1completed
NCT01975454
Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancertreatment1 / 2completed
NCT03724851
Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancertreatment1 / 2active_not_recruiting
NCT04233151
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and SafetyNo drug interventionstreatment3recruiting
NCT03035253
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancertreatment1terminated
NCT01941953
Metformin and 5-fluorouracil for Refractory Colorectal Cancer.treatment2completed
NCT05039177
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignanciestreatment1 / 2active_not_recruiting
NCT01001377
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancertreatment3completed
NCT00959647
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Studytreatment2completed
NCT00803647
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Livertreatment2completed
NCT02587247
ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancerdiagnostic2completed
NCT05178745
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résectionNot AvailableNot Availablecompleted
NCT01507545
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)treatment2terminated
NCT04046445
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancertreatment1active_not_recruiting
NCT01270698
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancertreatment1completed
NCT03927898
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasistreatment2unknown_status
NCT05854498
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancertreatment2recruiting
NCT06347198
Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancertreatment0recruiting
NCT05368805
Fruquintinib DDI Study With P-gp and BCRP Substratesother1completed
NCT03174405
Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.treatment2completed
NCT05970705
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRCtreatment2recruiting
NCT00890305
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alonetreatment2completed
NCT01867697
Nordic 8 - A Phase II Trialbasic_science2completed
NCT06208397
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver MetastasesNo drug interventionsNot AvailableNot Availablerecruiting
NCT00435097
Computer Assisted Early Detection of Liver Metastases From fMRI MapsNo drug interventionsNot AvailableNot Availableunknown_status
NCT04166383
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)treatment2completed
NCT00339183
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alonetreatment3completed
NCT01791361
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in EuropeNo drug interventionsNot AvailableNot Availablecompleted
NCT02611661
Local Ablative Strategies After Endovascular RadioembolizationNo drug interventionstreatment1terminated
NCT01281761
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)treatment2completed
NCT01693861
"Cancersensor" ChemotherapyNo drug interventionsNot AvailableNot Availablecompleted
NCT00176761
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccinetreatment2terminated
NCT04831528
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical StudyNot AvailableNot Availablenot_yet_recruiting
NCT03678428
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLMtreatment3terminated
NCT05593328
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutationtreatment2active_not_recruiting
NCT00852228
Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapytreatment2unknown_status
NCT04587128
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCtreatment2recruiting
NCT00779311
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancertreatment1terminated
NCT06195111
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)Not AvailableNot Availablenot_yet_recruiting
NCT04757311
Metastatic Colorectal Cancer. Real-World Data Analysis.No drug interventionsNot AvailableNot Availablecompleted
NCT03148093
The CHOICE RegistryNo drug interventionsNot AvailableNot Availableterminated
NCT06243393
Sacituzumab Govitecan in Metastatic Colorectal Cancertreatment2 / 3recruiting
NCT04446793
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal CancerNot AvailableNot Availableno_longer_available
NCT00574171
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinomatreatment2completed
NCT00961571
Sunitinib and Capecitabine for First Line Colon Cancertreatment2terminated
NCT01328171
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)treatment2completed
NCT00875771
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patientstreatment2completed
NCT05843188
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancertreatment2recruiting
NCT06134388
Sulfasalazine in Patients With Metastatic Colorectal Cancertreatment3recruiting
NCT02848807
Chemotherapy-related Toxicity, Nutritional Status and Quality of LifeNo drug interventionssupportive_careNot Availableunknown_status
NCT03017807
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal CancerNo drug interventionstreatment1unknown_status
NCT02466009
Regorafenib in Metastatic Colorectal Cancertreatment2completed
NCT00865709
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjectstreatment2completed
NCT02511756
Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)No drug interventionsdiagnosticNot Availableterminated
NCT06290856
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced MalignancyNo drug interventionsNot AvailableNot Availablerecruiting
NCT05609656
Electroporation and Immunotherapy in Metastatic Colorectal Cancertreatment2terminated
NCT00598156
Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarcevatreatment3completed
NCT02181556
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancertreatment2completed
NCT04247256
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRItreatment1 / 2unknown_status
NCT00873756
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancertreatment1completed
NCT05959356
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancertreatment2recruiting
NCT04430985
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancertreatment2withdrawn
NCT01143285
Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal CancerNo drug interventionspreventionNot Availablecompleted
NCT06553885
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCCtreatment2not_yet_recruiting
NCT01109615
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutationstreatment2terminated
NCT00531115
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.treatment2terminated
NCT02651415
Phase II Study of Perindopril and Regorafenib in mCRCtreatment2completed
NCT00254137
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.treatment2completed
NCT03225937
Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancertreatment2unknown_status
NCT05128032
Pressure-enabled Delivery in Radioembolization (TriNav Study)No drug interventionsdiagnosticNot Availablerecruiting
NCT05007132
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancertreatment2recruiting
NCT04786600
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 TrialNo drug interventionstreatment2terminated
NCT06411600
Combination Therapy for BRAF-V600E Metastatic CRCmtreatment2not_yet_recruiting
NCT02906059
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancertreatment1completed
NCT03376659
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinomatreatment1 / 2terminated
NCT02821559
Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancertreatment2completed
NCT01008475
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancertreatment1 / 2completed
NCT05382442
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancertreatment2recruiting
NCT01293942
IXO+A in mCRC With Liver-only Metastasestreatment2withdrawn
NCT01030042
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patientstreatment3completed
NCT04317599
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)No drug interventionsNot AvailableNot Availablecompleted
NCT03150706
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancertreatment2unknown_status
NCT06075849
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating AgentNo drug interventionstreatment1recruiting
NCT01858649
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.treatment2completed
NCT06543836
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancertreatment2recruiting
NCT05694936
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancertreatment2recruiting
NCT02322736
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORRNo drug interventionsNot AvailableNot Availablecompleted
NCT05462613
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancertreatment2 / 3recruiting
NCT01437618
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal CancerNot AvailableNot Availablecompleted
NCT03517618
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRCtreatment2completed
NCT00327119
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancertreatment2completed
NCT01927341
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumorsother1 / 2completed
NCT05004441
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancertreatment2recruiting
NCT00444041
Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancertreatment1 / 2completed
NCT05362617
mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapytreatment3unknown_status
NCT06202417
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world StudyNot AvailableNot Availablecompleted
NCT02965417
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patientstreatment2withdrawn
NCT06231017
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancertreatment2recruiting
NCT03130634
The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatmenttreatment4completed
NCT04854434
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutationstreatment2terminated
NCT03323424
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic CancersNo drug interventionstreatment2withdrawn
NCT02364024
Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal CarcinomasNo drug interventionsNot AvailableNot Availablecompleted
NCT02981524
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancertreatment2completed
NCT00932724
CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancertreatment2terminated
NCT01539824
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancertreatment2completed
NCT05747716
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRCtreatment2not_yet_recruiting
NCT02970916
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphismstreatment2completed
NCT03892096
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT03457896
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Statustreatment2unknown_status
NCT00345696
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.treatment2completed
NCT06341296
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancertreatment2recruiting
NCT03418558
Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.treatment2unknown_status
NCT03356158
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancertreatment1unknown_status
NCT00940758
Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base TherapyNo drug interventionstreatment1completed
NCT01693835
"Cancersensor": Circadian RhythmsNo drug interventionsNot AvailableNot Availablecompleted
NCT02404935
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)treatment2completed
NCT00399035
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancertreatment3completed
NCT00332163
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapytreatment2completed
NCT06495463
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in TaiwantreatmentNot Availablerecruiting
NCT05840263
Couple-Based Mindfulness Intervention for Metastatic Colorectal CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT00792363
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutationstreatment2completed
NCT02654639
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancertreatment2terminated
NCT01288339
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancertreatment2completed
NCT01363739
Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus BevacizumabNo drug interventionsNot AvailableNot Availableunknown_status
NCT01238939
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancertreatment1completed
NCT03626922
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patientstreatment1unknown_status
NCT02300922
Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancerother1 / 2terminated
NCT03010722
Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib MonotherapyNot AvailableNot Availablecompleted
NCT04444622
Immunotherapy for Third Line Metastatic Colorectal CancerNo drug interventionstreatment2recruiting
NCT04031625
Metastatic Colorectal Cancer DatabaseNo drug interventionsNot AvailableNot Availableunknown_status
NCT02128425
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancertreatment2unknown_status
NCT04008030
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)treatment3recruiting
NCT00286130
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancertreatment2completed
NCT00778830
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)treatment1 / 2completed
NCT02295930
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer PatientNo drug interventionstreatment2completed
NCT02350530
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typetreatment2unknown_status
NCT01075048
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancertreatment1 / 2completed
NCT05167448
A Study of ES104 in Patients With Metastatic Colorectal CancerNo drug interventionstreatment1 / 2active_not_recruiting
NCT00788957
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)treatment1 / 2completed
NCT01312857
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancertreatment2completed
NCT01321957
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancertreatment2completed
NCT01412957
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancertreatment3completed
NCT02497157
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancertreatment2completed
NCT01579357
Pharmacokinetics and Metabolic Activation of CapecitabineNo drug interventionsbasic_science2completed
NCT01345526
Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K CreamNo drug interventionssupportive_care2completed
NCT02119026
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancertreatment2completed
NCT04547166
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)treatment2 / 3recruiting
NCT01925274
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancertreatment2terminated
NCT01219920
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancertreatment3completed
NCT05023720
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT00828620
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab ProjectNo drug interventionsNot AvailableNot Availableterminated
NCT03454620
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapytreatment1 / 2completed
NCT06191120
FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer SubtypeNo drug interventionsdiagnosticNot Availablenot_yet_recruiting
NCT03274882
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapiestreatment2completed
NCT03142282
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal CancerNo drug interventionstreatment2unknown_status
NCT01085331
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)treatment1 / 2terminated
NCT01523431
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patientstreatment2 / 3completed
NCT02068131
Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancertreatment2unknown_status
NCT03668431
Dabrafenib + Trametinib + PDR001 In Colorectal Cancertreatment2unknown_status
NCT03940131
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFRtreatment2unknown_status
NCT00853931
Biomarker - Panitumumab Response With KRAS Wild Type MCCNot AvailableNot Availablecompleted
NCT03982173
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumorstreatment2withdrawn
NCT02641873
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancertreatment1completed
NCT02699073
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenibtreatment2completed
NCT03828227
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.other3active_not_recruiting
NCT03485027
Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal CancerNo drug interventionstreatment2completed
NCT05933876
The Impact of Radiotherapy on Oligometastatic CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT00954876
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancertreatment2withdrawn
NCT05281276
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)treatment1recruiting
NCT00910676
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitorsprevention2completed
NCT03357276
Mix Vaccine for Metastatic Colorectal CancerNo drug interventionstreatment1 / 2completed
NCT00138060
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinantstreatment4completed
NCT03306394
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).treatment3completed
NCT02842294
Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT05652894
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancertreatment3not_yet_recruiting
NCT01183494
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patientstreatment1completed
NCT04232891
Early Detection of Relapses in Stage IV Colorectal Cancer PatientsNo drug interventionsNot AvailableNot Availableunknown_status
NCT00457691
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancertreatment3completed
NCT01175291
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancertreatment2withdrawn
NCT06118762
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancertreatment4recruiting
NCT01858662
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumorstreatment2terminated
NCT00819780
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumorstreatment2completed
NCT02469480
Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.supportive_care2completed
NCT02547480
LifePearl-Iri Pharmacokinetic StudyNo drug interventionstreatmentNot Availablecompleted
NCT03263429
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancertreatment1 / 2completed
NCT05330429
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)treatment2terminated
NCT02934529
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximabtreatment3active_not_recruiting
NCT03380689
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancertreatment1withdrawn
NCT02102789
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasistreatment3recruiting
NCT01966289
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)treatment1completed
NCT03279289
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimentreatment2completed
NCT00414492
Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT01225744
Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapytreatment2completed
NCT01810744
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or GlioblastomaNo drug interventionsdiagnosticNot Availablecompleted
NCT01860144
An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT04097444
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRCtreatment2unknown_status
NCT02605044
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancertreatment3terminated
NCT02260440
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancertreatment2completed
NCT01533740
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer PatientsNot AvailableNot Availablecompleted
NCT05299840
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal CancerNo drug interventionsotherNot Availablerecruiting
NCT00931840
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinomatreatment2unknown_status
NCT02942901
Clinical Evaluation of PET-CT for Staging of Colorectal Lung MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT00459901
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancertreatment2terminated
NCT06049901
Nitazoxanide in Patients With Metastatic Colorectal Cancertreatment3recruiting
NCT04397601
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal CancerNot AvailableNot Availableunknown_status
NCT02090101
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancertreatment2completed
NCT01801904
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancertreatment2active_not_recruiting
NCT00508404
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancertreatment2completed
NCT01532804
2nd-line Treatment of Metastatic Colorectal Cancertreatment2terminated
NCT01754272
A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchNo drug interventionsNot AvailableNot Availableunknown_status
NCT03117972
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levelstreatment2active_not_recruiting
NCT01915472
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancertreatment2withdrawn
NCT04854668
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancertreatment3active_not_recruiting
NCT02077868
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentNo drug interventionstreatment3unknown_status
NCT00780169
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancertreatment1completed
NCT05016869
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancertreatment1 / 2unknown_status
NCT00989469
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutationtreatment1 / 2completed
NCT05217446
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancertreatment2recruiting
NCT00642746
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)treatment2terminated
NCT06218810
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancertreatment2recruiting
NCT02448810
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancertreatment2terminated
NCT00636610
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancertreatment2completed
NCT06029010
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United StatesNot AvailableNot Availablecompleted
NCT06321081
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCtreatment2recruiting
NCT02624895
ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st LineNo drug interventionsNot AvailableNot Availablecompleted
NCT00326495
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancertreatment2completed
NCT05183295
Medical Food for the Dietary Management of Metastatic Colorectal CancerNo drug interventionstreatmentNot Availablewithdrawn
NCT01144195
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapytreatment2unknown_status
NCT00145314
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancertreatment3completed
NCT06099314
Fruquintinib in the Cross-line Treatment of Refractory mCRCNot AvailableNot Availablerecruiting
NCT04776655
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBtreatment3unknown_status
NCT01550055
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancertreatment2 / 3completed
NCT00411450
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatmenttreatment2completed
NCT03043950
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)Not AvailableNot Availablecompleted
NCT02249650
To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.No drug interventionstreatment1completed
NCT04852250
Centralized Tumour Board and Secondary Intervention Rate in mCRCNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT02503150
Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal CancerNo drug interventionstreatment3unknown_status
NCT01103323
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapytreatment3completed
NCT06221423
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal CancerNot AvailableNot Availablerecruiting
NCT05375708
Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sitestreatment2not_yet_recruiting
NCT05522738
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancertreatment1 / 2recruiting
NCT01786538
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidinestreatment3withdrawn
NCT03712943
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancertreatment1completed
NCT02211443
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal CancerNo drug interventionstreatment1unknown_status
NCT02848443
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancertreatment1completed
NCT06109883
LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patientstreatment1not_yet_recruiting
NCT01843725
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancerstreatment1completed
NCT05378867
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRCtreatment3unknown_status
NCT04627142
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutationtreatment1terminated
NCT01468623
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6No drug interventionstreatment4terminated
NCT03350126
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumabtreatment2active_not_recruiting
NCT03567629
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancertreatment2unknown_status